AI assistant
LIGAND PHARMACEUTICALS INC — Director's Dealing 2021
Jun 8, 2021
31289_dirs_2021-06-07_dbee18c9-1899-42d0-8aee-d0ba46e26787.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-06-04
Reporting Person: KOZARICH JOHN W (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-06-04 | Common Stock | A | 630 | $0.0 | Acquired | 34782 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-04 | Non-Qualified Stock Option (right to buy) | $115.39 | A | 3269 | Acquired | 2031-06-04 | Common Stock (3269) | Direct |
Footnotes
F1: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
F2: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 04, 2021. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.